Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Income: 2009-2024

Historic Net Income for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to -$372.2 million.

  • Iovance Biotherapeutics' Net Income fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Net Income of -$372.2 million as of FY2024, which was up 16.18% from -$444.0 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Net Income ranged from a high of -$342.3 million in FY2021 and a low of -$444.0 million during FY2023.
  • For the 3-year period, Iovance Biotherapeutics' Net Income averaged around -$404.0 million, with its median value being -$395.9 million (2022).
  • Its Net Income has fluctuated over the past 5 years, first fell by 15.67% in 2022, then grew by 16.18% in 2024.
  • Yearly analysis of 4 years shows Iovance Biotherapeutics' Net Income stood at -$342.3 million in 2021, then declined by 15.67% to -$395.9 million in 2022, then fell by 12.16% to -$444.0 million in 2023, then rose by 16.18% to -$372.2 million in 2024.